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Introduction
Alzheimer’s disease (AD) is characterized by impairment in
cognition, function, and behavior. As disease progresses over
time, these impairments translate into increased patient
dependence on others, resulting in higher need for informal
(unpaid) care from family and friends, formal (paid) care, and
medical care. Existing research of AD treatments has typically
focused on separate measures of cognition and function as
discrete, specific clinical trial endpoints, with behavioral
impacts treated separately as secondary or exploratory
endpoints. Conversely, global measures such as the clinical
impression of change have been utilized to determine the
overall impact of the disease, though these measures do not
provide any granularity regarding level of impact or change
over time. 
An alternative method is to try to take a broader view that
incorporates as many of these discrete clinical endpoints
possible. While clinical trial endpoints provide important
information on the efficacy of AD treatments, they may not be
relevant to decision makers trying to gauge the impact of the
disease and/or the value of treatments. Assessing multiple trial
endpoints also can lead to confusion for decision makers if
treatments do not impact all endpoints similarly, especially if
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Abstract: Aim: While clinical endpoints provide important information on the efficacy of treatment in controlled
conditions, they often are not relevant to decision makers trying to gauge the potential economic impact or value
of new treatments. Therefore, it is often necessary to translate changes in cognition, function or behavior into
changes in cost or other measures, which can be problematic if not conducted in a transparent manner. The
Dependence Scale (DS), which measures the level of assistance a patient requires due to AD-related deficits, may
provide a useful measure of the impact of AD progression in a way that is relevant to patients, providers and
payers, by linking clinical endpoints to estimates of cost effectiveness or value. The aim of this analysis was to
test the association of the DS to clinical endpoints and AD-related costs. Method: The relationship between DS
score and other endpoints was explored using the Predictors Study, a large, multi-center cohort of patients with
probable AD followed annually for four years. Enrollment required a modified Mini-Mental State Examination
(mMMS) score 30, equivalent to a score of approximately 16 on the MMSE. DS summated scores (range: 0-
15) were compared to measures of cognition (MMSE), function (Blessed Dementia Rating Scale, BDRS, 0-17),
behavior, extrapyramidal symptoms (EPS), and psychotic symptoms (illusions, delusions or hallucinations).
Also, estimates for total cost (sum of direct medical cost, direct non-medical cost, and cost of informal
caregivers’ time) were compared to DS scores. Results:  For the 172 patients in the analysis, mean baseline
scores were: DS: 5.2 (SD: 2.0), MMSE: 23.0 (SD: 3.5), BDRS: 2.9 (SD: 1.3), EPS: 10.8%, behavior: 28.9%
psychotic symptoms: 21.1%. After 4 years, mean scores were: DS: 8.9 (SD: 2.9), MMSE: 17.2 (SD: 4.7), BDRS:
5.2 (SD: 1.4), EPS: 37.5%, behavior: 60.0%, psychotic symptoms:  46.7%. At baseline, DS scores were
significantly correlated with MMSE (r=-0.299, p<0.01), BDRS (r=0.610, p<0.01), behavior (r=.2633, p=0.0005),
EPS (r=0.1910, p=0.0137) and psychotic symptoms (r=0.253, p<0.01); and at 4-year follow-up, DS scores were
significantly correlated with MMSE (r=-0.3705, p=0.017), BDRS (r=0.6982, p<0.001). Correlations between DS
and behavior (-0.0085, p=0.96), EPS (r=0.3824, p=0.0794), psychotic symptoms (r=0.130, ns) were not
statistically significant at follow-up. DS scores were also significantly correlated with total costs at baseline
(r=0.2615, p=0.0003) and follow-up (r=0.3359, p=0.0318). Discussion:  AD is associated with deficits in
cognition, function and behavior, thus it is imperative that these constructs are assessed in trials of AD treatment.
However, assessing multiple endpoints can lead to confusion for decision makers if treatments do not impact all
endpoints similarly, especially if the measures are not used typically in practice. One potential method for
translating these deficits into a more meaningful outcome would be to identify a separate construct, one that takes
a broader view of the overall impact of the disease. Patient dependence, as measured by the DS, would appear to
be a reasonable choice – it is associated with the three clinical endpoints, as well as measures of cost (medical
and informal), thereby providing a bridge between measures of clinical efficacy and value in a single, transparent
measure. 
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the measures are typically not used in clinical practice.
Measures that link trial endpoints to clinically and patient
relevant measures could provide more transparency and inform
decision making for patients, their families, healthcare
providers and payers.
One potential method for translating these multiple trial
endpoints into a more meaningful outcome would be to identify
a separate construct, one that takes a broader view of the
overall impact of the disease, but also provide granularity
regarding level of impact or change over time. Recently, the
concept of dependence began to receive attention from the
research community (1). To this end, the Dependence Scale
(DS) was developed to directly measure the amount of
assistance AD patients need due to impairments in cognition,
function and behavior (2). The relationship between
dependence and specific clinical endpoints such as cognition,
function, and behavior, and the translation of these clinical
endpoints into health and economic outcomes via dependence
are conceptualized in Figure 1. Impairments in cognition
contribute to AD patients’ increased dependence on others,
either directly (for example, need for reminders of person, place
or time), or indirectly through functional impairments.
Similarly, functional impairments may directly translate to
increased dependence (loss of activities of daily living means a
patient needs more assistance in these activities), and
behavioral problems may lead to increased supervisory needs.
As the trajectory of changes in these constructs may differ
across patients and/or time, translating their impact into a
concept such as dependence could allow for better
characterization of the overall impact of these varying
impairments as they relate to economic outcomes such as
resource utilization and cost; as well as impacts on health
related quality of life (HRQOL). Research into the content of
the DS shows that the DS measures related but distinct aspects
of disability in AD and that the concept resonates with reports
from both patients and caregivers on the impact of the disease
(3, 4).
Figure 1
Translating Clinical Endpoints into Health Outcomes via
Dependence
While impairments in cognition, function and behavior
would be expected to explain much of the variation in an AD
patient’s dependence level, it is likely that other aspects (e.g.,
comorbid conditions) would also play a part not only in
explaining dependence, but also in relating to economic and
humanistic outcomes.
In this report we examine empirically the relationship
between patients’ DS scores and clinical endpoints (cognition,
function, behavior) and economic endpoints (direct medical,
direct non-medical, informal care costs). We compare the
strengths of the relationships with different endpoints. Results
reported here are summarized from earlier studies (5).
The sample used for this report is drawn from the Predictors
II cohort. Patients who were mildly demented were recruited
from three University-based AD centers in the US and followed
every 6 months, with annual assessment in economic outcomes.
All subjects met DSM-III-R criteria for primary degenerative
dementia of the Alzheimer type and NINDS-ADRDA criteria
for probable AD. Enrollment required a modified Mini-Mental
State examination (mMMS) score 30, equivalent to a score of
approximately 16 on the Folstein Mini-Mental State
Examination (MMSE). The analysis data includes patients who
were followed up to 4 years. The typical patient in the analysis
sample was female (58%), 76 years old, white, and had over 14
years of education. At baseline, average DS score was 5.2
(sd=2.2), indicating a mild level of dependence, with average
MMSE at 22.1 (sd=3.6) and average BDRS score at 3.5
(sd=2.1). Behavioral problems (41.6%) were common. About a
third (30.2%) had psychotic symptoms, 20.5% had depressive
symptoms, and 14.5% had extrapyramidal signs (EPS). On
average, patients had fewer than one comorbid condition
(mean=0.8, sd=0.9); almost half of the patients (47.8%) did not
have any comorbid conditions.
Dependence Scale
The Dependence Scale (DS) consists of 13 items,
representing a wide range of levels of care required by a
patient, from relatively subtle items such as needing reminders
or advice to more gross forms such as needing to be fed (2). All
items deal with patients’ needs. In some cases, the need is only
for supervision, without any specific tasks linked to the need.
The instrument is designed to be administered to a reliable
informant who lives with the patient or one who is well
informed about the patient’s daily activities and needs. With the
exception of the first two items (needs reminders to manage
chores, needs help to remember important things such as
appointments) which are coded as 0 (no), 1 (occasionally, at
least once a month), and 2 (frequently, at least once a week),
responses to the rest of the items are coded dichotomously and
indicate whether the patient requires assistance in a particular
item (0=no, 1=yes). The total DS score is the sum of scores on
all 13 items (range=0-15), and provides a continuous index of
progressively greater dependence on others. Table 1 details the
questions in the Dependence Scale.
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The Dependence Scale Questionnaire
A. Does the patient need reminders or advice to manage chores, do shopping,
cooking, play games, or handle money?
B. Does the patient need help to remember important things such as
appointments, recent events, or names of family or friends?
C. Does the patient need frequent (at least once a month) help finding
misplaced objects, keeping appointments, or maintaining health or safety
(locking doors, taking medication)?
D. Does the patient need household chores done for him/her?
E. Does the patient need to be watched or kept company when awake?
F. Does the patient need to be escorted when outside?
G. Does the patient need to be accompanied when bathing or eating?
H. Does the patient have to be dressed, washed, and groomed?
I. Does the patient have to be taken to the toilet regularly to avoid
incontinence?
J. Does the patient have to be fed?
K. Does the patient need to be turned, moved, or transferred?
L. Does the patient wear a diaper or a catheter?
M. Does the patient need to be tube fed?
Items A and B are coded as follows: no, 0; occasionally (ie, at least once a month), 1;
frequently (ie, at least once a week), 2. The other items are coded as follows: no, 0; yes, 1.
Total Dependence Scale score is the sum of scores on all 13 items (range=0-15).
Clinical Endpoints
We assessed the relationship between DS and the following
clinical endpoints: (1) Patients’ cognitive limitation was
measured by MMSE; (2) Functional impairment was measured
by the Blessed Dementia Rating Scale (BDRS) Parts I
(Instrumental Activities of Daily living, IADLs) and II (Basic
Activities of Daily living, BADLs); (3) Patients’ psychotic,
behavioral, and depressive symptoms were measured by the
Columbia University Scale for Psychopathology in Alzheimer’s
Disease (CUSPAD), a semi-structured interview administered
by a physician or a trained research technician; and (4)
Patients’ extrapyramidal signs (EPS) were measured by the
Unified Parkinson’s Disease Rating Scale (UPDRS). At
baseline, total DS scores were significantly correlated with
MMSE (r=-0.299, p<0.01), BDRS (r=0.610, p<0.01), behavior
(r=.2633, p=0.0005), EPS (r=0.1910, p=0.0137) and psychotic
symptoms (r=0.253, p<0.01); and at 4-year follow-up, DS
scores were significantly correlated with MMSE (r=-0.3705,
p=0.017), BDRS (r=0.6982, p<0.001). Correlations between
DS and behavior (-0.0085, p=0.96), EPS (r=0.3824, p=0.0794),
psychotic symptoms (r=0.130, ns) were not statistically
significant at follow-up.
Economic Endpoints
We took the perspective of the society and examined three
economic endpoints, including direct medical care, direct non-
medical care, and informal care. All resources used by the
patient and caregiver were reported. Direct medical care
included hospitalization, outpatient treatment/procedures,
assistive devices, and medications. Direct non-medical care
included care provided by home health aides, respite care, and
adult daycare. Informal care was measured by up to three
informal caregivers’ time for basic and instrumental activities
of daily living. At baseline, total DS scores were significantly
correlated with total costs (r=0.2615, p=0.0003), direct non-
medical cost (r=0.30212, p<0.0001),  informal hours per week
(r=0.26019, p=0.0008); and at 4-year follow-up, DS scores
were significantly correlated with total costs (r=0.3359,
p=0.0318), direct non-medical cost (r=0.35728, p=0.0035), and
informal hours per week (r=0.30700, p=0.0122). Figure 2
presents data on the relationship between total DS score and
direct medical and non-medical costs.
Figure 2
Medical and non-medical cost by dependence scale
Clinical and Policy Implications
AD is associated with impairments in cognition, function
and behavior, thus it is important that these constructs are
assessed in trials of AD treatment. However, if treatments do
not impact all trial endpoints similarly, assessing multiple
endpoints can lead to confusion for decision makers, including
patients’ families, healthcare providers, and payers. This is
especially problematic if the measures used in clinical trials are
typically not used in clinical practice. One potential method for
translating these AD related impairments into a more
meaningful outcome would be to identify a construct that takes
a broader view of the overall impact of the disease, and that
takes into account differences in the trajectory of changes in
these multiple constructs that differ across patients and/or time.
In this paper we summarize evidence that patient dependence,
as measured by the Dependence Scale, provides a potentially
useful method for translating clinical results into meaningful
outcomes. Results show that the Dependence Scale scores
correlate well with measures of cognition and function as well
as economic endpoints. Relationship observed at baseline is
consistent over time, supporting its use for longitudinal studies.
The lack of correlation between DS and patients’ psychotic,
behavioral, and depressive symptoms at year 4 merits
discussion. We believe these results may be due to the
roughness of the measures used in this study. For example,
subcategories of extrapyramidal and psychotic symptoms were
grouped together and we only used dichotomous gradations of
severity. Additionally, behavioral and psychiatric symptoms in
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AD fluctuate over time. Particular symptoms can occur any
time during the course of AD; Persistence of these symptoms
also differs from symptom to symptom. The fact that
medications also can be effective in managing patients’
psychotic, behavioral, and depressive symptoms may further
lead to fluctuation in these symptoms from visit to visit.
Previous attempts to find a meaningful outcome with
relevant impact in the progression of dementia focused mostly
on the use of nursing home placement. The decision to
institutionalize a patient is influenced by many non-medical
factors such as existence of living family members, willingness
and ability of the family to provide care, geographic location of
family, financial and insurance status, and cultural beliefs.
Thus, while clearly relevant and meaningful from an economic
and humanistic standpoint, actual nursing home placement may
not always be a good proxy for a patient’s true level of
dependence or need for care. Unlike nursing home placement,
patients’ dependence, as measured by the Dependence Scale,
documents levels of needs directly and is independent of the
caregiving site or setting. In addition to be well-correlated with
clinical endpoints and measures of healthcare cost, the
Dependence Scale also describes AD progression in terms that
correspond with patient/caregiver perceptions of the impact of
AD on their lives. Therefore, DS is potential method for
translating multiple clinical endpoints into a more meaningful
outcome that is more transparent to decision makers, including
patients’ families, healthcare providers, and payers.
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